MaxCyte (MXCT) Projected to Announce Quarterly Earnings on Tuesday

MaxCyte logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • MaxCyte is expected to report Q3 2026 results after market close on November 10. Analysts forecast a loss of $0.08 per share and revenue of approximately $7.39 million.
  • In the previous quarter, MaxCyte reported an $0.08-per-share loss, beating estimates by $0.01, while revenue of $6.50 million was slightly below expectations.
  • The stock has a consensus “Hold” rating and a $5.00 average price target, despite trading near $1.41 and continuing to post negative profitability metrics.
  • Five stocks we like better than MaxCyte.

MaxCyte (NASDAQ:MXCT - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect the company to post earnings of ($0.08) per share and revenue of $7.39 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. MaxCyte had a negative return on equity of 18.92% and a negative net margin of 114.77%. The firm had revenue of $6.50 million for the quarter, compared to analyst estimates of $6.51 million. On average, analysts expect MaxCyte to post ($0.25) EPS for the current fiscal year and ($0.19) EPS for the next fiscal year.

MaxCyte Stock Performance

MaxCyte stock traded down $0.04 during trading on Tuesday, reaching $1.41. The company had a trading volume of 296,638 shares, compared to its average volume of 1,051,224. The firm has a market capitalization of $145.00 million, a PE ratio of -4.26 and a beta of 1.49. The firm's 50-day simple moving average is $1.26 and its 200 day simple moving average is $1.07. MaxCyte has a 1-year low of $0.64 and a 1-year high of $1.80.

Analyst Upgrades and Downgrades

MXCT has been the topic of several recent analyst reports. BTIG Research reaffirmed a "neutral" rating on shares of MaxCyte in a report on Monday, August 24th. Weiss Ratings raised shares of MaxCyte from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, October 22nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $5.00.

Check Out Our Latest Research Report on MXCT

About MaxCyte

(Get Free Report)

MaxCyte, Inc NASDAQ: MXCT is a life sciences company that develops technologies for engineering cells used in biopharmaceutical research and the development of cell-based therapies. Its platform is designed to help researchers modify cells efficiently for applications including cell therapy, gene editing, immuno-oncology and other advanced biological treatments.

The company's primary offering is the ExPERT platform, which combines Flow Electroporation technology with specialized instruments, single-use processing assemblies, software and related support services.

Read More

Earnings History for MaxCyte (NASDAQ:MXCT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MaxCyte Right Now?

Before you consider MaxCyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.

While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines